<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Small Cap Premium &amp; Dividend Income Fund Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/small-cap-premium-dividend-income-fund-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ONXX) Onyx Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354</link>
		<comments>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354#comments</comments>
		<pubDate>Tue, 16 Aug 2011 18:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81354</guid>
		<description><![CDATA[We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved sales of the company’s only marketed drug, Nexavar (sorafenib) for cancer, which came in at $245.7 million (up 4% year-over-year) during the quarter, Onyx Pharma’s revenues experienced a 1.2% decline, amounting to $68.0 million. Earnings were further reduced as a result of higher-than-expected operating expenses. While research and development (R&#38;D) spend went up 16.2% to $50.3 million, selling, general and administrative (SG&#38;A) expenses shot up 43.6% to $38.2 million. Increased expenses for the development of carfilzomib led to higher R&#38;D spend and an increase in employee headcount and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Keryx Biopharmaceuticals Cancer Drug Impresses</title>
		<link>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474</link>
		<comments>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474#comments</comments>
		<pubDate>Sat, 03 Oct 2009 22:08:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aeterna Zentaris Inc]]></category>
		<category><![CDATA[AEZS]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16474</guid>
		<description><![CDATA[Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the US, Canada and Mexico. The data was presented at the eighth International Kidney Cancer Symposium in Chicago. The candidate demonstrated efficacy, safety and tolerability in metastatic renal cell carcinoma (RCC) patients whose disease progressed after failing treatment with both a VEGF (vascular endothelial growth factor) receptor inhibitor and an mTOR (mammalian target of rapamycin) inhibitor. Even though the drug was well-tolerated, the most common adverse events were gastrointestinal discomfort and fatigue. RCC is the most common of all kidney tumors, accounting for 85% of the cases. The advanced form of the disease is resistant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

